论文部分内容阅读
目的 探讨重组人粒细胞集落刺激因子 (rhG -CSF)治疗严重急性呼吸综合征 (SARS)合并白细胞减少的疗效及其安全性。方法 用全自动血细胞分析仪检测 95例SARS急性期患者外周血白细胞计数、分类、红细胞及血小板 ,对白细胞小于 3.0× 10 9 L和中性粒细胞小于 2 .0× 10 9 L者给予rhG -CSF治疗 ,观察其疗效和安全性。结果 35例白细胞小于 3.0× 10 9 L和中性粒细胞小于 2 .0× 10 9 L的患者给予rhG -CSF治疗后 ,患者的白细胞、中性粒细胞、淋巴细胞和血小板显著增加 ,肺部炎症反应并未加重 ,住院时间明显缩短。 35例患者全部治愈出院 ,住院和随访期间无继发细菌、真菌、结核菌或二重感染。结论 SARS合并白细胞减少者应用rhG -CSF治疗 ,可显著改善外周血象 ,提高机体免疫功能 ,对预防继发感染可能有一定帮助。
Objective To investigate the efficacy and safety of recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of severe acute respiratory syndrome (SARS) associated with leukopenia. Methods Peripheral white blood cell count, classification, erythrocytes and platelets in 95 SARS patients were detected by automatic hematology analyzer. The patients with acute lymphocytic leukemia were treated with rhG - CSF treatment, observe its efficacy and safety. Results In 35 patients with leukocyte less than 3.0 × 10 9 L and neutrophils less than 2.0 × 10 9 L, the number of leucocytes, neutrophils, lymphocytes and platelets increased significantly after treatment with rhG-CSF. Inflammatory reaction did not aggravate, significantly shorter hospital stay. All 35 patients were cured and discharged without secondary bacterial, fungal, mycobacterial or double infections during hospitalization and follow-up. Conclusions The treatment of rhG-CSF with SARS complicated with leucopenia can significantly improve the peripheral blood and enhance immune function, which may be helpful to prevent secondary infection.